Updates on osteonecrosis of the jaw

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 3, 2010, Pages 200-206

  Yamashita, Junro ^a   McCauley, Laurie K ^b,c   Van Poznak, Catherine ^d  

^a Department of Biologic Materials and Sciences ^*  (United States)

^b Dental Research Center   (United States)

^c Medical School   (South Africa)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti angiogenesis; Bisphosphonate; Immunomodulation; Necrotic bone

Indexed keywords

ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; HUMAN; JAW; NEOPLASM; PATHOLOGY; RISK FACTOR;

ANGIOGENESIS INHIBITORS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW; NEOPLASMS; OSTEONECROSIS; RISK FACTORS;

EID: 78449277253     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833d303b     Document Type: Article

References (55)

1. Reid IR. Osteonecrosis of the jaw: Who gets it, and why? Bone 2009; 44:4-10
2. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents. Cancer Invest 2009; 27:221-226. A prospective study of patients with metastatic prostate cancer, receiving docetaxel, bevacizumab, thalidomide, prednisone, and zoledronic acid in which the incidence of ONJ was 18%, suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ
3. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Min Res 2007; 22:1479-1491.
4. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: A review. J Am Dent Assoc 2009; 140:864-875
5. Gliklich R, Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: The utility of a national registry. J Oral Maxillofac Surg 2009; 67 (Suppl 5):71-74
6. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67 (Suppl 5):61-70
7. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized phase 3 study. Eur J Cancer Suppl 2009; 7:2. Phase III data suggest that the incidence of ONJ is 1-2% in patients with metastatic breast cancer involving the bone who were treated with potent osteoclast inhibitors
8. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 2009; 7:11. Phase III data suggest that the incidence of ONJ is 1-2% in patients with metastatic bone disease who were treated with potent osteoclast inhibitors
9. Binkley N. Is Vitamin D the fountain of youth? Endocr Pract 2009; 15:590-596
10. Badros A, Goloubeva O, Terpos E, et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haemat 2008; 142:480-501
11. Adams JS, Hewison M. Update in Vitamin D. J Clin Endocrinol Metab 2010; 95:471-478
12. Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist 2008; 13:821-827
13. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; 27:2151-2156
14. Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84:397-400
15. Trump DL, Chadha MK, Sunga AY, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int 2009; 104:909-914
16. Otto S, Schuler K, Ihrler S, et al. Osteonecrosis or metastases of the jaw or both? Case report and review of the literature. J Oral Maxillofac Surg 2010; 68:1185-1188
17. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27:5356-5362. This cohort study between January 2000 and October 2008 of 1621 Greek patients with metastatic bone disease and receiving bisphosphonate therapy identified 80 cases of ONJ. The investigators identified that the following factors were associated with ONJ: Dentures, history of dental extraction, and use of zoledronic acid. The data did not demonstrate an association with smoking, periodontitis, or root canal treatment
18. Abraham F, Saxena D, Dalvi M, et al. Molecular analysis of bacteria associated with osteonecrosis of the jaw molecular analysis of bacteria associated with osteonecrosis of the jaw IADR/AADR/CADR. In: 87th General Session and Exhibition; 1-4 April 2009
19. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763
20. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6:395-404
21. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19:2091-2092
22. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26:4037-4038
23. Ayllon J, Launay-Vacher V, Medioni J, et al. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: Cumulative toxicity profile? Ann Oncol 2009; 20:600-601
24. Brunello A, Saia G, Bedogni A, et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44:173-175
25. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122:181-188. The authors present data from adverse event, reported from three large clinical trials investigating bevacizumab in the treatment of patients with locally advanced or metastatic breast cancer. The analysis included 3560 patients and did not demonstrate an association between bevacizumab and risk of ONJ
26. McArthur HL, Estilo C, Huryn J, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 2008; 26:9588
27. Sarasquete ME, Garca-Sanz R, Marn L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709-2712
28. Michaelis UR, Fisslthaler B, Barbosa-Sicard B, et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005; 118:5489-5498
29. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67 (Suppl 1): 96-106
30. Cardoso L, Herman BC, Verborgt O, et al. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009; 24:597-605
31. Kozloff KM, Volakis LI, Marini JC, Caird MS. Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res 2010. [Epub ahead of print] Both the deposition and retention of bisphosphonates were assessed using a fluorescent bisphosphonate marker in rats. The study found that the degree of bisphosphonate deposition and retention was affected by bone quantity and bone turnover rate. In themandible, the bisphosphonatemarker was found mainly in the temporomandibular joints and alveolar bone surrounding the roots of the molars
32. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010; 25:606-616. The study demonstrated that bisphosphonates are deposited and localized in osteocytes lacunae either close to the bone surface or vascular channels in the cortical bone using fluorescently labeled risedronate. The study also showed evidence that CD14high bone marrow monocytes are capable of uptake a large amount of bisphosphonates in vivo
33. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008; 66:987-994
34. Huja SS, Beck FM. Bone remodeling in maxilla, mandible, and femur of young dogs. Anat Rec (Hoboken) 2008; 291:1-5
35. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010; 25:98-105
36. Li D, Gromov K, Proulx ST, et al. Effects of antiresorptive agents on osteomyelitis: Novel insights into the pathogenesis of osteonecrosis of the jaw. Ann N Y Acad Sci 2010; 1192:84-94. This study describes an osteomyelitis animal model in which antiresorptive agents were utilized in a murine trans-tibial infected pin model. Antiresorptives (alendronate and osteoprotegerin) were found to decrease lymphatic drainage and prevent the removal of necrotic bone harboring bacteria. Parallels were drawn to the condition of osteonecrosis of the jaw
37. Simoni D, Gebbia N, Invidiata FP, et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem 2008; 51:6800-6807
38. Agrati C, Cimini E, Sacchi A, et al. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 2009; 182:522-529
39. Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and nonresorbing cells. Bone 2008; 42:848-860
40. Masuda T, Deng X, Tamai R. Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation. Int Immunopharmacol 2009; 9:1115-1121
41. Chen YJ, Chao KS, Yang YC, et al. Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells. Immunopharmacol Immunotoxicol 2009; 31:499-508
42. Sonis ST, Watkins BA, Lyng GD, et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009; 45:164-172
43. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138:563-579
44. Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 2010. [Epub ahead of print] This study reported the development of ONJ-like legions following tooth extractions in mice that were under a combination therapy of bisphosphonate and dexamethasone. In such mice the adaptive regulatory T cells (Tregs) were suppressed. When those rats received the systemic infusion of mesenchymal stem cells, Tregs were restored and ONJ-like lesions were healed
45. Hokugo A, Christensen R, Chung E, et al. Increased prevalence of bisphosphonate- related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010; 25:1337-1349
46. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281
47. Kobayashi Y, Hiraga T, Ueda A, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010; 28:165-175
48. Hikita H, Miyazawa K, Tabuchi M, et al. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 2009; 27:663-672
49. Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood 2010; 115:140-149
50. Hirbe AC, Roelofs AJ, Floyd DH, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009; 44:908-916
51. Mantovani A, Sica A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 2010; 22:231-237
52. Lesclous P, Abi Najm S, Carrel JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 2009; 45:843-852
53. Sedghizadeh PP, Kumar SK, Gorur A, et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009; 140:1259-1265
54. Cardaropoli G, Araujo M, Lindhe J. Dynamics of bone tissue formation in tooth extraction sites: An experimental study in dogs. J Clin Periodontol 2003; 30:809-818
55. Griffith JF, Yeung DKW, Antonio GE, et al. Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation. Radiology 2006; 241:831-838.